監管
FDA approves Merck's enlicitide, the first oral PCSK9 inhibitor for high cholesterol
The U.S. FDA approved Merck's LIPFENDRA (enlicitide), described as the first once-daily oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia. It enters a category previously served only by injectable PCSK9 therapies.
大盤 開啟原文 ↗